Trial reportRheumatology international2025
Axial spondyloarthritis, psoriatic arthritis and systemic lupus erythematosus share common molecular features based on post-hoc analysis of serum biomarkers.
Trial report in Rheumatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study of Ustekinumab in Subjects With Active Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF Alpha Naive Subjects With Active Radiographic Axial Spondyloarthritis
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Subjects With Active Radiographic Axial Spondyloarthritis
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), and systemic lupus erythematosus (SLE) are distinct rheumatological diseases with common molecular features. This study explored tissue-associated remodelling endotypes using blood-based biomarkers reflecting interstitial matrix and basement membrane remodelling. Baseline serum samples from radiographic axSpA (r-axSpA) (NCT02437162/NCT02438787) (n = 66), PsA (NCT03158285) (n = 267) and SLE (NCT02349061) (n = 97) studies were analysed alongside healthy donors. Biomarkers of collagen turnover (C1M, C2M, C3M, C4M, C6M, C10C, PRO-C1, PRO-C2, PRO-C3, PRO-C4, PRO-C6) were measured by immunoassays and compared using Kruskal-Wallis tests. K-means clustering (k = 3) of r-axSpA, PsA and SLE patients was applied to construct disease endotype clusters. Serum C1M, C3M, C4M, C6M, and PRO-C3 markers were elevated up to 4.2-fold (p <0.003) in r-axSpA, PsA and SLE patients versus healthy donors. Serum C10C marker was elevated up to 1.2-fold (p < 0.001) in PsA and SLE patients versus healthy donors. PsA and r-axSpA patients showed increased levels of serum PRO-C2, PRO-C4, and PRO-C6 up to 1.4-fold (p < 0.025) versus healthy donors. Three endotypes were identified: 1) hypertrophic (n = 171), with elevated C10C, low PRO-C4 and lower disease activity reflected by CRP, ASDAS (r-axSpA), PASI, DAS28 (PsA) and joint scores (SLE); 2) fibrolytic (n = 156), with high tissue degradation, increased PRO-C4 and severe inflammation with elevated disease activity; 3) fibrogenic (n = 93), with increased cartilage degradation (C2M), fibrosis (PRO-C3, PRO-C6) and moderate disease activity. Tissue-associated remodelling profiles highlight heterogeneity within each disease and common molecular features, revealing clinically relevant subgroups. Identifying biomarker endotypes may guide targeted treatments and inform drug repurposing across rheumatological diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.